DMAC - Diamedica shows mixed results for kidney disease therapy in mid-stage study

Diamedica Therapeutics (DMAC) has lost ~12.1% in the pre-market after the company announced clinically meaningful results for two cohorts from a Phase 2 trial for DM199 in chronic kidney disease ((CKD)).The trial is designed to evaluate the effect of DM199, a recombinant (synthetic) form of human tissue protein kallikrein-1 in three cohorts of patients with CKD.The cohorts are African Americans ((AA)), non-diabetic and hypertensive (Cohort 1, n=12), IgA Nephropathy (IgAN) (Cohort 2, n=16) and diabetic kidney disease ((DKD)) (Cohort 3, n=28).In cohorts 1 and 2, DM199 was found to cause clinically meaningful improvements in kidney function, the company said adding that it has also reduced blood pressure by clinically significant levels in hypertensive subjects (Cohorts 1 and 3).However, in cohort 3, despite a significant decrease in blood pressure by -5/1 mmHg (n=28), the estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio ((UACR)) levels were stable.The stabilizing eGFR and decline in UACR is a

For further details see:

Diamedica shows mixed results for kidney disease therapy in mid-stage study